Varamir
Desk
News
Calendar
Pricing
Saved
Search
tickers or companies
⌘K
Start free
· no card
Sign in
LXRX compared with ENGN: revenue, margins and what each company keeps, and the suppliers and customers both name
LXRX
Lexicon Pharmaceuticals, Inc.
Change
Mkt cap
Revenue
Revenue
ENGN
enGene Therapeutics Inc.
Change
Mkt cap
Revenue
Revenue
vs
Compare
LXRX
Lexicon Pharmaceuticals, Inc.
vs
ENGN
enGene Therapeutics Inc.
Price
Mkt cap
Revenue
Revenue
Change
Change
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Save comparison
Copy link
Revenue flow
Desk
News
Calendar
Saved
Search
Revenue flow
Supply chain
Price
Co-movers
Event sensitivity
Earnings history
Price
Supply-chain overlap
Revenue flow
LXRX: latest quarter is a loss; flow not drawable. ENGN: latest quarter not drawable.
Method
›
LXRX
Lexicon Pharmaceuticals, Inc.
Change
1.42
▼
−4.05%
· post 1.42
Mkt cap
$631.8M
Revenue
$692,000
Q2 FY26
Revenue
$144M
FY25
ENGN
enGene Therapeutics Inc.
Change
1.50
▼
−1.86%
· post 1.50
Closed
Oct 30 '26
Mkt cap
$102.5M
Revenue
—
Revenue
—
vs
Compare
Closed
Oct 30 '26
LXRX
Lexicon Pharmaceuticals, Inc.
vs
ENGN
enGene Therapeutics Inc.
1.42
▼
−4.05%
post 1.42
Price
1.50
▼
−1.86%
post 1.50
$631.8M
Mkt cap
$102.5M
Q2 FY26
$692,000
Revenue
—
FY25
$144M
Revenue
—
Change
Change
LXRX
1.42
▼
−4.05%
vs
ENGN
1.50
▼
−1.86%
Closed
Oct 30 '26
Price
rebased to 0%
1D
1W
1M
3M
YTD
1Y
5Y
1D
1W
1M
3M
YTD
1Y
5Y
LXRX, solid
ENGN, dashed
Supply-chain overlap
direct ties · both sides
Sources
›
direct ties · both sides
Only LXRX
12
BMY
Bristol-Myers Squibb
supplier
VTRS
Viatris
customer
NVO
Novo Nordisk A/S
customer
—
RFL NO.4 Limited Partnership
unlisted
supplier
8 more · LXRX chain
›
Shared
0
No disclosed counterparties: ENGN.
Only ENGN
0
None
Role chip = supplier or customer
—
= no ticker (unlisted)
Source: SEC EDGAR